1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow IO Biotech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer PD-L1/IDO Peptide Vaccine, Pembrolizumab - High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 | Active not recruiting | University of California, Davis | 6 | 2023-04-19 | 2026-07-16 |
| IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi) - NSCLC | Phase 1 / Phase 2 | Completed | IO Biotech | 109 | 2018-08-22 | 2022-04-21 |
pembrolizumab (2) · Carboplatin (1) · Pemetrexed (1)
Germany (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)
James Spicer, MD Prof (1) · Mamta Parikh (1)
2018 (1), P30CA093373 (1)